OpenURL Connection Search

Select item for more details and to access through your institution.

AFS/FEF Student Technology Contest: Effect of Carbon and Aluminum on Hardness and Notch Toughness in Lightweight, Advanced High-Strength Steels.
Published in:
International Journal of Metalcasting, 2020, v. 14, n. 1, p. 272, doi. 10.1007/s40962-019-00376-3
By:
- Van Dyke, R.;
- Bartlett, L. N.
Publication type:
Article
Understanding the Role of Inclusions on the Dynamic Fracture Toughness of High Strength Lightweight FeMnAl Steels.
Published in:
International Journal of Metalcasting, 2019, v. 13, n. 2, p. 286, doi. 10.1007/s40962-018-0273-9
By:
- Vaz Penna, R.;
- Bartlett, L. N.;
- Constance, T.
Publication type:
Article
Minimizing Phosphorus Pickup During Melting and Casting of Lightweight Fe-Mn-Al-C Steels.
Published in:
International Journal of Metalcasting, 2018, v. 12, n. 1, p. 164, doi. 10.1007/s40962-017-0152-9
By:
- Bartlett, L. N.;
- Rahman, R.;
- Torres, A.
Publication type:
Article
Bone marrow staging in patients with non-Hodgkin's lymphoma: is flow cytometry a useful test?
Published in:
1998
By:
- Naughton, Michael J.;
- Hess, Jay L.;
- Zutter, Mary M.;
- Bartlett, Nancy L.;
- Naughton, M J;
- Hess, J L;
- Zutter, M M;
- Bartlett, N L
Publication type:
journal article
MACOP-B +/- radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford results according to prognostic indices.
Published in:
1993
By:
- Bartlett, Nancy L.;
- Kwak, Larry W.;
- Horning, Sandra J.;
- Bartlett, N L;
- Kwak, L W;
- Horning, S J
Publication type:
journal article
Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
Published in:
2001
By:
- Bartlett, Nancy L.;
- Petroni, Gina R.;
- Parker, Barbara A.;
- Wagner, Nina D.;
- Gockerman, Jon P.;
- Omura, George A.;
- Canellos, George P.;
- Cooper, M. Robert;
- Johnson, Jeffrey L.;
- Peterson, Bruce A.;
- Bartlett, N L;
- Petroni, G R;
- Parker, B A;
- Wagner, N D;
- Gockerman, J P;
- Omura, G A;
- Canellos, G P;
- Robert, M;
- Johnson, J L;
- Peterson, B A
Publication type:
journal article
COMBINING CD19‐4‐1BBL (RO7227166) WITH GLOFITAMAB IS SAFE AND SHOWS EARLY EFFICACY IN PATIENTS SUFFERING FROM RELAPSED OR REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA.
Published in:
Hematological Oncology, 2023, v. 41, p. 136, doi. 10.1002/hon.3163_91
By:
- Hutchings, M.;
- Dickinson, M.;
- Carlo‐Stella, C.;
- Morschhauser, F.;
- Bosch, F.;
- Gritti, G.;
- Townsend, W.;
- Bartlett, N. L.;
- Cartron, G.;
- Ghesquieres, H.;
- Houot, R.;
- Walter, H.;
- Offner, F.;
- Christiansen, A.;
- Dimier, N.;
- Jamois, C.;
- Harrop, E.;
- Herter, S.;
- Hölzlwimmer, G.;
- Keelara, A.
Publication type:
Article
MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY.
Published in:
Hematological Oncology, 2023, v. 41, p. 122, doi. 10.1002/hon.3163_83
By:
- Sehn, L. H.;
- Bartlett, N. L.;
- Matasar, M.;
- Schuster, S. J.;
- Assouline, S.;
- Giri, P.;
- Kuruvilla, J.;
- Shadman, M.;
- Cheah, C. Y.;
- Fay, K.;
- Ku, M.;
- Nastoupil, L.;
- Wei, M. C.;
- Yin, S.;
- To, I.;
- Hu, N.;
- Min, J.;
- Penuel, E.;
- Belousov, A.;
- Coimbra, A.
Publication type:
Article
RADIOMICS REFLECTING BOTH TUMOR AND HOST FEATURES IMPROVES OUTCOME PREDICTION IN FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2023, v. 41, p. 94, doi. 10.1002/hon.3163_58
By:
- Rebaud, L.;
- Capobianco, N.;
- Spottiswoode, B.;
- Cottereau, A.;
- Trotman, J.;
- Feugier, P.;
- Nastoupil, L. J.;
- Bachy, E.;
- Flinn, I. W.;
- Haioun, C.;
- Ysebaert, L.;
- Bartlett, N. L.;
- Tilly, H.;
- Casasnovas, R.;
- Ricci, R.;
- Portugues, C.;
- Meignan, M.;
- Morschhauser, F.;
- Buvat, I.
Publication type:
Article
NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826.
Published in:
Hematological Oncology, 2023, v. 41, p. 33, doi. 10.1002/hon.3163_5
By:
- Herrera, A. F.;
- LeBlanc, M.;
- Castellino, S. M.;
- Li, H.;
- Rutherford, S. C.;
- Evens, A. M.;
- Davison, K.;
- Punnett, A.;
- Hodgson, D.;
- Parsons, S. K.;
- Ahmed, S.;
- Casulo, C.;
- Bartlett, N. L.;
- Tuscano, J. M.;
- Mei, M. G.;
- Hess, B. T.;
- Jacobs, R.;
- Saeed, H.;
- Torka, P.;
- Hu, B.
Publication type:
Article
Venetoclax combined with R‐ICE (VICER) for second line treatment of diffuse large B cell lymphoma refractory or relapsed after initial chemoimmunotherapy.
Published in:
Hematological Oncology, 2023, v. 41, p. 436, doi. 10.1002/hon.3164_321
By:
- Caimi, P. F.;
- Cashen, A.;
- Gallogly, M.;
- Winter, A.;
- Boughan, K.;
- Ghobadi, A.;
- Jagadeesh, D.;
- Cooper, B.;
- Mehta‐Shah, N.;
- Dean, R.;
- Metheny, L.;
- Pohlman, B.;
- Bartlett, N. L.;
- de Lima, M.;
- Kahl, B. S.;
- Hill, B. T.
Publication type:
Article
CAMIDANLUMAB TESIRINE EFFICACY AND SAFETY IN AN OPEN‐LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS (PTS) WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.75_2879
By:
- Zinzani, P. L.;
- Carlo‐Stella, C.;
- Hamadani, M.;
- Herrera, A. F.;
- Ansell, S. M.;
- Radford, J.;
- Maddocks, K.;
- Kline, J.;
- Savage, K. J.;
- Bartlett, N. L.;
- Caimi, P. F.;
- Negievich, Y.;
- Cruz, H. G.;
- Wang, L.;
- Wuerthner, J.;
- Collins, G. P.
Publication type:
Article
CALGB 50801 (ALLIANCE): PET ADAPTED THERAPY IN BULKY STAGE I/II CLASSIC HODGKIN LYMPHOMA (CHL)
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.72_2879
By:
- LaCasce, A. S.;
- Dockter, T.;
- Ruppert, A.;
- Kostakoglu, L.;
- Schöder, H.;
- Hsi, E. D.;
- Bogart, J. A.;
- Cheson, B. D.;
- Wagner‐Johnston, N. D.;
- Abramson, J. S.;
- Maddocks, K. J.;
- Leonard, J. P.;
- Bartlett, N. L.
Publication type:
Article
COPY NUMBER VARIATION ANALYSIS IDENTIFIES DISTINCT GENOMIC FEATURES IN ADULT BURKITT LYMPHOMA.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.67_2879
By:
- Dreval, K.;
- Thomas, N.;
- Gerhard, D. S.;
- Hilton, L. K.;
- Wong, J.;
- Abramson, J. S.;
- Bartlett, N. L.;
- Bethony, J.;
- Bowen, J.;
- Bryan, A. C.;
- Casper, C.;
- Dyer, M.;
- Gastier‐Foster, J. M.;
- Grande, B. M.;
- Greiner, T.;
- Griner, N. B.;
- Gross, T. G.;
- Harris, N. L.;
- Irvin, J. D.;
- Jaffe, E.
Publication type:
Article
BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY IN ADOLESCENTS AND YOUNG ADULTS (AYAS) WITH STAGE III OR IV HODGKIN LYMPHOMA: A SUBGROUP ANALYSIS FROM THE PHASE 3 ECHELON‐1 STUDY.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.38_2879
By:
- Crosswell, H. E;
- LaCasce, A. S.;
- Bartlett, N. L;
- Straus, D. J;
- Savage, K. J;
- Zinzani, P. L;
- Collins, G. P;
- Fanale, M. A;
- Fenton, K;
- Dong, C;
- Miao, H. H;
- Grigg, A. P
Publication type:
Article
BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN SUBJECTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) (TRIAL IN PROGRESS)
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.166_2880
By:
- Bartlett, N. L.;
- Yasenchak, C. A.;
- Ashraf, K. K.;
- Harwin, W. N.;
- Sims, R. B.;
- Nowakowski, G. S.
Publication type:
Article

Found: 16